Find and Pitch Jounalists, Get Your Story Covered

Tags: enterprise accelerators open source ai hardware

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Amlenetug receives FDA Fast Track Designation - 20 days ago
2	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Posdinemab Receives FDA Fast Track Designation for Treatment of Alzheimer Disease - about 2 months ago Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation - 3 months ago FDA Panel Endorses Donanemab to Treat Early-Stage Alzheimer Disease - 9 months ago FDA Grants Orphan Drug Designation for CAN-2409 to Treat Pancreatic Cancer - 11 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Axsome to send Alzheimer’s disease drug to FDA, despite mixed Phase 3 results - 2 months ago STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug - over 1 year ago
4	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Ozempic for Alzheimer's? What Drives Brain Age; Primary Care Alzheimer's Guideline - 2 months ago Alzheimer's Data Withdrawn - 4 months ago Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence - 11 months ago Opening Blood-Brain Barrier to Deliver Alzheimer's Drug Shows Promise - about 1 year ago Alzheimer's Vaccines Are Back; Streamlining Prior Authorization; Rare APOE Variant - over 1 year ago Subcutaneous Alzheimer's Drug May Be on the Horizon - over 1 year ago
5	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Roche’s TIGIT troubles continue, a novel Alzheimer’s target misses the mark, and other biotech news - 3 months ago STAT+: It’s time for the FDA to halt Cassava Sciences’ Alzheimer’s clinical trials - over 1 year ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	A win for Apellis, a setback for Astellas - 3 months ago The biotech news you missed this week - 8 months ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about drug shortages, what drugmakers didn’t tell Alzheimer’s trial patients and more - 4 months ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - 12 months ago STAT+: Pharmalittle: We’re reading about Lilly Alzheimer’s drug adcomm, Amylyx ALS drug flop, and more - 12 months ago STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more - about 1 year ago STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors - about 1 year ago STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs - over 1 year ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - over 1 year ago
8	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	Amy Abernethy, former No. 2 at FDA, outlines new company’s plans to streamline clinical research - 5 months ago
9	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 5 months ago 3 recent FDA adcomm rejections — and why they matter - over 1 year ago
10	Nicole Lou MedPage Today Medical reporter @medpagetoday. Bird advocate. undisclosed remote location medical reporting	Ocaliva's Takedown by FDA Panel - 6 months ago

Journalists covering FDA accelerated approval ,Office of Inspector General ,aducanumab approval,clinical trial data,alzheimer disease